Ultragenyx Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ultragenyx Pharmaceutical (RARE).

Price Target Range — 11 Quarters

Analyst Consensus — 22 Analysts

20Buy

2Hold

Consensus RatingOverweight# Analysts22Avg. Consensus PT$68Upside to Avg. PT+165.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 28, 2026	Wells Fargo	Michael Turrin	PT Raise	Overweight	$46→$50
Aug 25, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$75→$80
Aug 21, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$67→$74
Aug 20, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$81→$83
Aug 20, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$45→$58
Aug 20, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$45→$46
Aug 20, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$96→$103
Aug 10, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$50
Aug 5, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$47→$45
Aug 4, 2026	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$43→$35
Jul 7, 2026	RBC Capital	Luca Issi	PT Raise	Outperform	$35→$40
May 21, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$84→$96
May 8, 2026	Wedbush	Laura Chico	PT Cut	Neutral	$27→$26
May 8, 2026	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$52→$43
May 6, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$45→$47
May 6, 2026	Wedbush	Laura Chico	PT Cut	Neutral	$27→$26
Apr 29, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$44→$43
Apr 16, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$50→$67
Mar 24, 2026	Goldman Sachs	Salveen Richter	Downgrade	Buy→Neutral	$61→$25
Mar 12, 2026	JP Morgan	Anupam Rama	PT Cut	Overweight	$120→$74

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $50

Wells Fargo analyst Michael Turrin maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $46 to $50.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $80

JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $75 to $80.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74

Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $67 to $74.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $81 to $83.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58

Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $45 to $58.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $46

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $45 to $46.

Benzinga Newsdesk

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $50

PRO
JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $80

PRO
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83

PRO
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58

PRO
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $46

People Also Watch

People Also Watch

Benzinga

Benzinga

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $50

PROJP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $80

PROMorgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74

PROCanaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83

PROCitigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58

PROWells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $46

People Also Watch

People Also Watch

PRO
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $50

PRO
JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $80

PRO
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83

PRO
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58

PRO
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $46